ZIOPHARM Oncology, Inc. Presents Positive Phase II Data for ZIO-201 in Soft Tissue and Bone Sarcomas at Connective Tissue Oncology Society (CTOS) Annual Meeting
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of positive data from an ongoing Phase II study of ZIO-201 used in soft tissue and bone sarcomas at the Connective Tissue Oncology Society (CTOS) Annual Meeting which was held in Seattle, Washington from November 1-3, 2007.